Posts by: Patricia Inacio PhD

News

BeiGene‘s investigational antibody tislelizumab was well-tolerated and induced at least stable disease in 53 percent of urothelial carcinoma patients treated in a Phase 1a/b clinical trial. The data was presented ... Read more

February 13, 2018February 13, 2018

Targovax Therapy and Chemo Trigger Immune Response to Mesothelioma, Phase 1/2 Trial Shows

News

ONCOS-102 triggered an immune response against mesothelioma and was safe, the initial results of a Phase 1/2 clinical trial of a combo therapy shows. Targovax designed its virus-based ONCOS-102 to strengthen the ... Read more

February 8, 2018February 8, 2018

Opdivo-Yervoy Combo Delays Disease Progression in Certain Patients with Advanced NSCLC, Study Shows

News

Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high mutation burden lived longer without the disease progressing when receiving Opdivo (nivolumab) plus Yervoy (ipilimumab), compared to chemotherapy, ... Read more

February 1, 2018

BioLineRx’s AGI-134 Induces Tumor Regression, Improves Survival in Melanoma Mice

News

Treating melanoma mouse models with an intratumoral injection of BioLineRx‘s AGI-134 induced complete tumor regression in more than half the animals and significantly increased their survival, a preclinical study showed. The ... Read more

January 19, 2018January 19, 2018

Digital Map of T-cell Receptors Could Help Predict Cancer Patient Responses to Immunotherapy

News

Scientists at Johns Hopkins have created a digital map that addresses the variability of T-cell receptors, the chemical “antennas” that recognize antigens and trigger an immune response. While still under development, ... Read more

December 19, 2017

AM0010 Shows Promise in Phase 1 Trial for Advanced Metastatic Renal Cell Carcinoma

News

New data from a Phase 1 clinical trial shows that ARMO BioSciences‘ immunotherapy AM0010 (pegilodecakin), alone or in combination with immune checkpoint inhibitors, shows high and durable clinical responses in patients with ... Read more

December 8, 2017

More Mutations in Melanoma Cells Predict Better Responses to Immunotherapy

News

A higher number of mutations in melanoma cells, coupled with increased T-cell activation, increases survival of melanoma patients who received adoptive T-cell immunotherapy, researchers have shown. The study, “Mutational and ... Read more

December 5, 2017December 5, 2017

Phase 3 Opdivo Trial Ends Early After Showing Better Survival Rates than Docetaxel in NSCLC

News

A Phase 3 study comparing Opdivo (nivolumab) to Taxotere (docetaxel) in patients with advanced non-small cell lung cancer (NSCLC) who didn’t respond to platinum-based chemotherapy was ended early after an independent ... Read more

December 1, 2017December 1, 2017

EMA to Review Opdivo-Yervoy Combo as Treatment for Renal Cancer

News

The European Medicines Agency (EMA) will review Bristol-Myers Squibb’s application seeking to expand the indications for Opdivo (nivolumab) plus Yervoy (ipilimumab) to include intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC). ... Read more

November 17, 2017

Combining Opdivo with BMS-986205 Shows Promise in Advanced Cervical, Bladder Cancers

News

Bristol-Myers Squibb announced encouraging results of combining Opdivo (nivolumab) with the investigational IDO1 Inhibitor, BMS-986205, in patients with advanced cancers and heavily treated with other therapies. The data stems from ... Read more